14 completed, 14 recruiting, 9 terminated, 8 active not recruiting. 32 Phase 2, 27 Phase 1, 1 Early Phase 1, 1 Phase 3.
Follow Verastem, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Avutometinib/Defactinib and mFOLFIRINOX Combination Therapy in Pancreatic Adenocarcinoma Avutometinib (VS-6766) + Defactinib (VS-6063) - Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Not yet recruiting | University of Virginia | 31 | 2026-10-01 | 2026-09-17 |
| Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) avutometinib + defactininb combination - Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer | Phase 2 | Not yet recruiting | Verastem, Inc. | 2 | 2026-08-03 | 2026-08-05 |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer VS-7375, cetuximab, panitumumab - Colorectal Cancer | Phase 2 | Recruiting | Verastem, Inc. | 150 | 2026-07-28 | 2026-10-21 |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer VS-7375 - Non-Small Cell Lung Cancer | Phase 2 | Recruiting | Verastem, Inc. | 105 | 2026-07-22 | 2026-10-19 |
| A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer VS-7375, cetuximab (or panitumumab if α-gal IgE+ or cetuximab reaction) - Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS | Phase 2 | Recruiting | Verastem, Inc. | 185 | 2026-06-16 | 2026-10-19 |
| Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer Avutometinib, defactinib, Everolimus - Phase IB, Avutometinib | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 31 | 2026-05-13 | 2026-06-29 |
| Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma Stereotactic body radiotherapy, Defactinib, Avutometinib - Pancreatic Adenocarcinoma, Cancer of the Pancreas | Phase 2 | Recruiting | Washington University School of Medicine | 36 | 2026-04-10 | 2026-04-15 |
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab - Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Verastem, Inc. | 616 | 2025-06-24 | 2026-10-15 |
| 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours Avutometinib, Defactinib, Temozolomide - Glioblastoma Multiforme (GBM), Glioblastoma Multiform (Grade IV Astrocytoma) | Phase 1 / Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 182 | 2024-11-15 | 2026-01-21 |
| A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients Avutometinib (VS-6766) + Defactinib (VS-6063) - Low Grade Serous Ovarian Cancer, Ovarian Cancer | Phase 2 | Active not recruiting | Verastem, Inc. | 16 | 2024-10-30 | 2025-12-17 |
| Avutometinib and Defactinib in Diffuse Gastric Cancer Avutometinib, Defactinib - Gastric Cancer, Stomach Cancer | Phase 2 | Recruiting | Ryan H. Moy, MD, PhD | 27 | 2024-10-28 | 2025-11-04 |
| A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer Avutometinib, Defactinib, Letrozole - Low-Grade Serous Ovarian Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 20 | 2024-04-29 | 2026-07-20 |
| Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma Defactinib, Avutometinib, Encorafenib - Cutaneous Melanoma, Brain Metastases | Phase 1 / Phase 2 | Recruiting | University of Utah | 33 | 2024-03-20 | 2025-12-03 |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer avutometinib, Defactinib, Pegylated liposomal doxorubicin - Low Grade Serous Ovarian Cancer | Phase 3 | Recruiting | Verastem, Inc. | 270 | 2024-03-18 | 2026-10-07 |
| A Study of Avutometinib and Defactinib in People With Thyroid Cancer Avutometinib, Defactinib - Thyroid Cancer | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 30 | 2023-08-16 | 2026-10-15 |
| Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma Avutometinib, Biospecimen Collection, Defactinib - Glioblastoma, Recurrent Glioblastoma | Early Phase 1 | Active not recruiting | Emory University | 14 | 2023-07-28 | 2025-12-15 |
| Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel - KRAS Activating Mutation, Metastatic Cancer | Phase 1 / Phase 2 | Active not recruiting | Verastem, Inc. | 40 | 2023-03-22 | 2025-09-02 |
| A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer Avutometinib (VS-6766), Defactinib - Mesonephric Gynecologic Cancer | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2023-03-15 | 2026-10-08 |
| VS-6766+Abema+Fulv in Met HR+/HER- BC VS-6766, Abemaciclib, Fulvestrant - Breast Cancer, Hormone Receptor-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Adrienne G. Waks | 63 | 2023-02-23 | 2026-04-30 |
| A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib Avutometinib (VS-6766) + defactinib - Endometrioid Cancer, Mucinous Ovarian Cancer | Phase 2 | Recruiting | University of Oklahoma | 55 | 2023-02-06 | 2025-10-22 |
Showing 20 of 50. Sign in to see all of them.
Pancreatic Neoplasms (12) · Carcinoma, Non-Small-Cell Lung (7) · Ovarian Neoplasms (6) · Neoplasm Metastasis (5) · Lung Neoplasms (4) · Colorectal Neoplasms (3) · Mesothelioma, Malignant (3) · Neoplasms (3) · COVID-19 (2) · Glioblastoma (2) · Mesothelioma (2) · Adenoma (1) · Appendiceal Neoplasms (1) · Biliary Tract Neoplasms (1) · Brain Neoplasms (1)
defactinib (35) · Cetuximab (4) · Gemcitabine (4) · pembrolizumab (4) · 130-nm albumin-bound paclitaxel (3) · Paclitaxel (3) · RO5126766 (3) · Carboplatin (2) · Everolimus (2) · Letrozole (2) · PND 1186 (2) · VS-5584 (2) · duvelisib (2) · Albumin-Bound Paclitaxel (1) · Anastrozole (1)
United States (41) · United Kingdom (10) · Australia (7) · Canada (6) · France (6) · Spain (5) · Belgium (4) · Italy (4) · Japan (4) · Netherlands (3) · Germany (2) · New Zealand (2) · Poland (2) · Puerto Rico (2) · Denmark (1)
Hagop Youssoufian, MD (6) · MD Verastem (6) · Rachel Grisham, MD (4) · Hagop Youssoufian (3) · Adrienne G Waks, MD (1) · Alan Ho, MD, PhD (1) · Anna Minchom, MB BCh, FRCP, MD (Res) (1) · Ardaman S. Shergill, MD (1) · Arsen Osipov, MD (1) · Carl DeSelm, M.D., Ph.D. (1) · Christian Ottensmeier (1) · Christina Washington, MD (1) · David E Gerber, M.D. (1) · Dean Fennell (1)
PMID 37598000, PMID 40644648, PMID 26334219, PMID 27025608, PMID 30785827, PMID 33128873, PMID 34663687, PMID 35285277, PMID 37953814, PMID 38493021, PMID 39375168, PMID 40579546, PMID 41384753, PMID 41790275, PMID 42814800
2015 (1), 2017 (1), P30CA138292 (1), R01CA248917 (1)